• 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8

RHEACELL GmbH & Co. KG

RHEACELL is dedicated to the development of pharmaceuticals based on ABCB5-positive (ABCB5+) mesenchymal stem cells as a platform technology. An integral part of RHEACELL's research program is the development of novel and innovative therapeutic approaches and their review in clinical trials. In the end, patients should be offered new treatment options for diseases that have not been or are insufficiently treatable.


As part of the development process of stem cell-based pharmaceuticals RHEACELL makes use of several patents hold by Harvard University/Cambridge that are worldwide exclusively licensed to RHEACELL. Markus Frank, M. D., Professor of Pediatrics and Dermatology at Harvard Medical School, is assisting RHEACELL as scientific advisor. He has particular expertise in stem cell research.


Since mid 2016 RHEACELL is recruiting patients with chronic venous ulcers (CVU) for a phase I/IIa multicenter clinical trial with autologous (patient-derived) ABCB5+ mesenchymal stem cells.


Since the end of 2017 RHEACELL is also recruiting patients with chronic venous ulcers (CVU) and diabetic foot ulcers (DFU) for two phase I/IIa multicenter clinical trials and patients with peripheral arterial occlusive disease (PAOD) for a phase I/IIa multicenter, randomized, placebo-controlled, double-blind clinical trial with allogeneic (donor-derived) ABCB5+ mesenchymal stem cells.


Since the end of 2018 RHEACELL is also recruiting patients with recessive dystrophic epidermolysis bullosa (RDEB) for an international FDA approved phase I/IIa multicenter clinical trial with allogeneic (donor-derived) ABCB5+ mesenchymal stem cells. The product of RHEACELL, based on ABCB5 positive mesenchymal stem cells, has been granted the Orphan Drug Designation for the treatment of RDEB in the EU and USA.


Since March 2019, RHEACELL is also recruiting patients with acute-on-chronic liver failure for a phase I/IIa multicenter clinical trial with allogeneic (donor-derived) ABCB5+ mesenchymal stem cells and patients with limbal stem cell deficiency for an international FDA approved phase I/IIa clinical trial with ABCB5+ limbal stem cells. The limbal stem cell product, based on ABCB5 positive stem cells, of RHEACELL has also been granted Orphan Drug Designation in the EU and Fast Track Designation in the USA.


Furthermore, studies are being planned in cooperation with various research centers in the fields of kidney regeneration and tumor diseases.


to the study centers – Germany >>

to the study centers – Worldwide >>


Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok